Which price belongs to this edge for Embody Tirzepatide?

The canonical catalog records $129 a month, continuing for Compounded tirzepatide injection, checked 22 August 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.

Is medication part of that number in the Embody figure?

The canonical Embody offer marks medication as included for Tirzepatide. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.

Can another route use these facts for Embody Tirzepatide?

This record is limited to Compounded tirzepatide injection in Weekly subcutaneous injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another Tirzepatide formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.

Does an empty state list prove coverage for Embody Tirzepatide?

The current record lists Louisiana as restricted for this vertical. Confirm eligibility directly because provider coverage can change. The state record is only one access field. Embody must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific Tirzepatide prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.

Which page ranks alternatives for Embody Tirzepatide?

Use the canonical Tirzepatide program comparison. It reads current provider and price data from the registry and preserves the compounded-tirzepatide treatment route. Compare Embody only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Provider treatment guide · checked 22 August 2026

Embody Tirzepatide

Published by Telehealth LedgerSource checked 22 August 2026Editorial policy

Embody lists Compounded tirzepatide injection at $129 a month, continuing. Medication is included in that catalog price. Readers comparing Embody's compounded tirzepatide program with other tirzepatide offers and who need a treatment-specific, not provider-generic, starting point. The commercial terms were checked 22 August 2026; state access, clinician approval, dispensing details, and personal suitability remain separate questions.

Visit Embody Read the full review

Embody Tirzepatide treatment illustration

$129a month, continuing

Includedmedication in catalog price

Weekly subcutaneous injectioncataloged format

22 August 2026commercial terms checked

1 listed restrictionstate-access record

The short answer for this provider-treatment pair: Embody Tirzepatide

Resolve whether Embody's compounded tirzepatide listing is the relevant program to compare, with its route and current catalog terms distinguished from Embody's compounded semaglutide offer.

Readers comparing Embody's compounded tirzepatide program with other tirzepatide offers and who need a treatment-specific, not provider-generic, starting point. A fair reading keeps Embody's Tirzepatide listing separate from adjacent products that may use a related medication or sit in the same provider catalog.

Do not blur this product with adjacent options: Compounded tirzepatide injection

Compounded tirzepatide injection is cataloged as a compounded product in Weekly subcutaneous injection format. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review as approved drug products. Ask for the exact formulation and dispensing pharmacy before purchase. That status is central to this Embody guide because a related medication name does not make branded, compounded, oral, nasal, and injectable products interchangeable.

Weekly subcutaneous injection is the exact format attached to Embody's offer, while the canonical owner describes this comparison unit as Compounded tirzepatide injection. Route matters for product identification, fulfillment, source selection, and a fair price comparison. This draft does not supply dose instructions, route conversions, or a claim that another formulation would have the same evidence, safety profile, convenience, or outcome.

The catalog-backed cost view: Embody

Embody's canonical offer lists Compounded tirzepatide injection at $129 a month, continuing. The number is computed from the same registry fields used by the treatment comparison, not copied into this draft as a fixed editorial amount. That connection matters because a future catalog correction can update the displayed commercial fact without leaving this guide on a stale, contradictory figure.

The canonical offer marks medication as included in the displayed price. It does not verify that labs, every consultation, supplies, expedited shipping, or future dose changes are included unless the source says so. Those items remain checkout questions. For Embody Tirzepatide, read inclusion as one field in the offer record, not as proof that every service surrounding the prescription is free. The dated source establishes the advertised basis; it does not independently audit the final checkout, dispensing event, or quality of care.

Billing terms to settle before payment: Embody Tirzepatide

The catalog has both a continuing option at $129 a month, continuing and a prepaid option at $119 a month, paying $1,428 for 12 months up front. Those are different commitments. Compare the total charged today, the renewal path, and the cancellation deadline rather than treating the lowest monthly equivalent as month to month. This is why Telehealth Ledger keeps introductory, recurring, upfront, effective-monthly, and commitment fields separate for Embody's Tirzepatide offer. A monthly equivalent can be useful, but only when the required payment and term remain visible beside it.

The Embody source for this edge was checked on 22 August 2026. Before paying for Tirzepatide, compare the amount charged today with the amount charged later, the number of months purchased, the renewal date, the cancellation window, and the refund boundary after clinical or pharmacy processing. A current catalog price cannot safely answer those policy questions unless the cited provider evidence does.

Coverage, eligibility, and fulfillment: Tirzepatide

The canonical provider record lists Louisiana as restricted for weight-loss programs. That list is a dated catalog fact, not proof of eligibility everywhere else. Confirm the current state rule before intake. The Tirzepatide access check belongs near the price because a low published figure has little decision value when Embody cannot serve the reader's state or the selected product cannot be fulfilled there.

For Embody Tirzepatide, the consumer brand, administrative platform, clinical group, and dispensing pharmacy can be different entities. A provider page may describe a national service while licensure, product rules, and pharmacy coverage narrow actual fulfillment. Ask which clinician entity would review the intake and which licensed pharmacy would dispense this exact product in the reader's state before treating access as settled.

What the provider dossier adds: Embody

Modern Metabolic Medicine, Inc. is recorded in the Embody dossier as administrator. Administrative operator named in the terms. These entities can perform different jobs, so the consumer-facing brand should not automatically be described as the clinician or dispensing pharmacy for Tirzepatide.

Cancellation deadline: Embody requires notice at least 72 hours before billing. The dossier also preserves this boundary for Embody's Tirzepatide decision: Affiliate landing compresses prepay prices: The $69 and $119 headlines are twelve-month effective rates; current month-to-month prices are higher. Carry that dated limitation into checkout instead of assuming a catalog price settles operations, fulfillment, or eligibility.

Use the broader owner for ranking: Tirzepatide

The linked Tirzepatide owner is the right place to rank Embody beside other cataloged offers. Use the same fields for every row: continuing price, introductory period, required prepayment, medication inclusion, product type, delivery format, verification date, and state evidence. If two offers use different routes or one price excludes medication, a simple lowest-number verdict would not be a like-for-like conclusion.

From this Embody guide, the comparison link resolves to the canonical Tirzepatide program owner, and the provider action uses the catalog's treatment-specific destination when one exists. Otherwise it uses the matching weight-loss destination. That routing keeps the reader in the correct treatment lane and avoids sending a Tirzepatide decision to an unrelated offer.

When this offer belongs on the shortlist: Embody Tirzepatide

Embody's listing answers the basic commercial question for Tirzepatide, but it cannot answer personal eligibility, medical fit, pharmacy assignment, or an individual outcome. Those limits belong in the decision, not in fine print after it.

Readers comparing Embody's compounded tirzepatide program with other tirzepatide offers and who need a treatment-specific, not provider-generic, starting point. Treat the provider link as a verification step: confirm the product name, price phase, medication inclusion, state rule, pharmacy, renewal date, and refund boundary before payment.

Common questions

Embody Tirzepatide FAQ

Which price belongs to this edge for Embody Tirzepatide?: The canonical catalog records $129 a month, continuing for Compounded tirzepatide injection, checked 22 August 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.
Is medication part of that number in the Embody figure?: The canonical Embody offer marks medication as included for Tirzepatide. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.
Can another route use these facts for Embody Tirzepatide?: This record is limited to Compounded tirzepatide injection in Weekly subcutaneous injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another Tirzepatide formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.
Does an empty state list prove coverage for Embody Tirzepatide?: The current record lists Louisiana as restricted for this vertical. Confirm eligibility directly because provider coverage can change. The state record is only one access field. Embody must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific Tirzepatide prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.
Which page ranks alternatives for Embody Tirzepatide?: Use the canonical Tirzepatide program comparison. It reads current provider and price data from the registry and preserves the compounded-tirzepatide treatment route. Compare Embody only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Sources and method

Telehealth Ledger checked provider pages, plan terms, and independent context on 22 August 2026. This page compares published commercial terms. It is not a rating, medical advice, or a guarantee that a clinician will prescribe treatment.